FDA Requires New GLP-1 Drug Warnings About a Potential Risk of Rare but Permanent Vision Loss

people per 100,000 per year, even without medication influences.

Against this backdrop, the FDA’s focus is on early recognition and rapid response. For health care professionals, the agency advises prompt counseling so patients know what to watch for and when to seek help. Sudden onset of painless decreased vision in one eye, the appearance of blind spots, tunnel vision, changes in color perception, or blurry or hazy central vision should all prompt immediate contact with a clinician. Patients who describe these symptoms should be referred urgently to an ophthalmologist

Leave a Reply

Your email address will not be published. Required fields are marked *